Skip to main content
. 2020 Nov 17;11:601555. doi: 10.3389/fmicb.2020.601555

Figure 3.

Figure 3

Selective inhibition of gene expression and replication of adenovirus type 5 by TAT-I24. (A) luciferase levels (mean ± SD from duplicate wells) of HEK293 cells treated with TAT (48–60) or TAT-I24 and infected with adenovirus-GFP-Luc vector for 24 h. (B) Relative hexon and CXCL8 mRNA levels from duplicate extractions of HEK293 cells treated with 10 μM TAT (48–60), TAT-I24, or DMSO and infected with adenovirus-GFP-Luc and with TNF-α (10 ng/ml) stimulation after 6 h for further 18 h. Data are expressed as % of vehicle-treated control. (C) Adenovirus genome copies from supernatants from duplicate treatments of infected HEK293 cells with a single dose of 10 μM TAT-I24 for 6 days (group A), with a single dose of 10 μM TAT-I24, and two additional doses of 5 μM TAT-I24 on days 2 and 4 (group B) or treated with 10 μM TAT-I24 24 h post-infection and two additional doses of 5 μM TAT-I24 on days 2 and 4 (group C). (D) Gaussia luciferase levels in the supernatants (mean ± SD from triplicate wells) expressed as % of vehicle-treated control from A549 cells transduced with recombinant reporter construct AAV-GLuc-3B and treated on the next day with increasing concentrations of TAT-I24 and infected with adenovirus 4, 5, or 19a/64.